Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
Tulmimetostat by MorphoSys for Endometrial Cancer: Likelihood of Approval
Tulmimetostat is under clinical development by MorphoSys and currently in Phase II for Endometrial Cancer. According to GlobalData, Phase II...
Tulmimetostat by MorphoSys for Sezary Syndrome: Likelihood of Approval
Tulmimetostat is under clinical development by MorphoSys and currently in Phase I for Sezary Syndrome. According to GlobalData, Phase I...
Tulmimetostat by MorphoSys for Mycosis Fungoides: Likelihood of Approval
Tulmimetostat is under clinical development by MorphoSys and currently in Phase I for Mycosis Fungoides. According to GlobalData, Phase I...
Tulmimetostat by MorphoSys for Fallopian Tube Cancer: Likelihood of Approval
Tulmimetostat is under clinical development by MorphoSys and currently in Phase I for Fallopian Tube Cancer. According to GlobalData, Phase...
Tulmimetostat by MorphoSys for Peritoneal Cancer: Likelihood of Approval
Tulmimetostat is under clinical development by MorphoSys and currently in Phase I for Peritoneal Cancer. According to GlobalData, Phase I...